Test, HPV DNA

Primary use
Diagnosis / Measurement / Monitoring
Type of medical device or related product
In vitro diagnostic tests
General vs. specific use (health condition)
Specific
Intended population age
Later adults (over 64 years)
Adults (20 to 64 years)
Adolescent (10 to 19 years)
Childhood (28 days to 9 years)
Intended population sex
All
Level of technical knowledge
Specialized clinical
Capital
No
Reusable
No
Requirements
None
WHO list of priority medical devices
Cancer management (2017)
Service delivery platforms / Healthcare levels
Second-level and third-level hospital services and specialized outpatient services
Healthcare unit
Laboratory
EMDN related code(s)
W0105041004
FULL GENOTYPIG HIGH-RISK + LOW-RISK HPV - NA REAGENTS
The code(s) and term(s) in this section were observed and retrieved from public databases and have not been validated by health regulatory authorities. Please consult your regulatory agency and EMDN site: https://webgate.ec.europa.eu/dyna2/emdn
GMDN related code(s)
49997
Human papillomavirus (HPV) high risk strain nucleic acid IVD, kit, nucleic acid technique (NAT) (A collection of reagents and other associated materials intended to be used for the qualitative and/or quantitative detection of nucleic acid from one or multiple high-risk strains of human papillomavirus (HPV) associated with cervical cancer, which may include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and/or 68 in a clinical specimen, using a nucleic acid technique (NAT).)
The medical device term(s), code(s) and definition(s) in this section were retrieved from databases external to WHO. As there might be more than one name, definition and “Nomenclature Code” related to the specific medical device, please consult https://gmdnagency.org GMDN ®. © GMDN Agency 2005-2024 
WHO Technical specifications
WHO related resources
Decommissioning
WHO resources on medical devices